What does Corvia Medical, Inc do?
Corvia Medical, Inc develops transcatheter cardiovascular devices that aim to improve the treatment of heart failure. Their flagship product, the Corvia Atrial Shunt, is designed to reduce elevated left atrial pressure, which is a key contributor to heart failure symptoms.
How much did they raise?
The company raised $55M in a series unknown round, with lead investors including Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, along with additional investor participation.
What are their plans for the money?
The funds will be used to complete the ongoing RESPONDER-HF trial—a double-blinded, randomized, sham-controlled, confirmatory study being conducted at over 65 institutions across three continents. Successful trial outcomes could validate the device's potential to reduce heart failure events and improve quality of life.
What have they achieved so far?
Corvia Medical has progressed to a global clinical trial phase with its Corvia Atrial Shunt device, highlighting its commitment and potential in transforming heart failure treatment.